Format

Send to

Choose Destination
Gut. 2019 Nov 28. pii: gutjnl-2019-319915. doi: 10.1136/gutjnl-2019-319915. [Epub ahead of print]

Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG).

Author information

1
Family Cancer Clinic, St Mark's Hospital, London, UK k.monahan@imperial.ac.uk.
2
Faculty of Medicine, Imperial College, London, UK.
3
Clinical Genetics, West of Scotland Genetics Services, Glasgow, Glasgow, UK.
4
Gastroenterology, Cardiff and Vale NHS Trust, Cardiff, UK.
5
Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.
6
CCGG, University of Edinburgh, Edinburgh, UK.
7
Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
8
Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
9
Faculty of Medicine & Health Sciences, Nottingham University, Nottingham, UK.
10
Head of Policy and Campaigns, Bowel Cancer UK, London, UK.
11
Genetic Medicine, Central Manchester University Hospitals Foundation Trust, Manchester, UK.
12
Polyposis Registry, St Mark's Hospital, London, UK.
13
Gastroenterology, University Hospital of North Tees, Stockton-on-Tees, UK.
14
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
15
Nuffield Department of Clinical Medicine, Wellcome Trust Centre for Human Genetics, Birmingham, UK.
16
Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
17
Family Cancer Clinic, St Mark's Hospital, London, UK.

Abstract

Heritable factors account for approximately 35% of colorectal cancer (CRC) risk, and almost 30% of the population in the UK have a family history of CRC. The quantification of an individual's lifetime risk of gastrointestinal cancer may incorporate clinical and molecular data, and depends on accurate phenotypic assessment and genetic diagnosis. In turn this may facilitate targeted risk-reducing interventions, including endoscopic surveillance, preventative surgery and chemoprophylaxis, which provide opportunities for cancer prevention. This guideline is an update from the 2010 British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland (BSG/ACPGBI) guidelines for colorectal screening and surveillance in moderate and high-risk groups; however, this guideline is concerned specifically with people who have increased lifetime risk of CRC due to hereditary factors, including those with Lynch syndrome, polyposis or a family history of CRC. On this occasion we invited the UK Cancer Genetics Group (UKCGG), a subgroup within the British Society of Genetic Medicine (BSGM), as a partner to BSG and ACPGBI in the multidisciplinary guideline development process. We also invited external review through the Delphi process by members of the public as well as the steering committees of the European Hereditary Tumour Group (EHTG) and the European Society of Gastrointestinal Endoscopy (ESGE). A systematic review of 10 189 publications was undertaken to develop 67 evidence and expert opinion-based recommendations for the management of hereditary CRC risk. Ten research recommendations are also prioritised to inform clinical management of people at hereditary CRC risk.

KEYWORDS:

colorectal cancer; colorectal surgery; genetic testing; inherited cancers; surveillance

PMID:
31780574
DOI:
10.1136/gutjnl-2019-319915
Free full text

Conflict of interest statement

Competing interests: KJM: Medical advisory board of Bowel Cancer UK, Lynch Syndrome UK. JH and FL: FAP trial (now closed) with funding awarded to NHS trust research facility. JE: Advisory board Lumendi, Boston Scientific; Speaker fees Olympus, Falk. MDR: Speaker fees: SwissSCWeb, Pentax; Research Grant: Olympus; Consultancy: Norgine.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center